NEW ANTIPLATELET DRUGS. PART 2

Por A. B. Sumarokov
Publicado em 2016-01-01

NEW ANTIPLATELET DRUGS (PART 1)

Por A. B. Sumarokov
Publicado em 2016-01-01

Coronary heart disase in haematological patients

Por A. B. Sumarokov
Publicado em 2008-12-01

CAN CLOPIDOGREL FULLY SUBSTITUTE WARFARIN AND DABIGATRAN IN ATRIAL FIBRILLATION?

Por A. B. Sumarokov
Publicado em 2013-08-01

RESTORATION OF ANTITHROMBOTIC THERAPY IN IBS PATIENTS AFTER EPISODE OF BLEEDING

Por A. B. Sumarokov, Y. V. Dotsenko
Publicado em 2017-11-01

Specific Antidotes for Direct Oral Anticoagulants in Life-Threatening Bleeding

Por A. B. Sumarokov, L. I. Buryachkovskaya, N. V. Lomakin
Publicado em 2019-01-01

Thrombocytopenia and prospective endovascular intervention in a patient with coronary artery disease

Por A. B. Sumarokov, L. I. Buryachkovskaya, N. V. Lomakin
Publicado em 2019-01-01

ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS

Por L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo
Publicado em 2016-01-01

Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients

Por A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
Publicado em 2020-03-01

Anti-aggregant therapy in patients with coronary heart disease and gastric ulcer

Por A. B. Sumarokov, L. I. Buryachkovskaya, M. V. Ezhov, I. A. Uchitel’, Yu. V. Dotsenko
Publicado em 2010-10-01

INDIVIDUAL APPROACH TO PATIENTS WITH INDICATION FOR ANTIPLATELET THERAPY. WHAT TO RELY ON IN CHOOSING THE THERAPY?

Por N. V. LOMAKIN, A. B. SUMAROKOV, Yu. V. DOTSENKO, I. A. UCHITEL, L. I. BURYACHKOVSKAYA
Publicado em 2017-12-01

Platelet activation and red blood cell changes in thrombotic and rheological disturbances among coronary heart disease patients

Por T. E. Shirokova, L. I. Buryachkovskaya, A. B. Sumarokov, I. A. Uchitel, E. G. Popov, A. V. Vavaev
Publicado em 2007-10-01